Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P15088 (
mast cell
)
14,925
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Stimulation of the receptor tyrosine kinase KIT by Stem Cell Factor (SCF) triggers activation of RAS and its downstream effectors. Proper KIT activation is essential for the maturation, survival and proliferation of mast cells. In addition, SCF activation of KIT is critical for recruiting mast cells to sites of infection or injury, where they release a mix of pro-inflammatory substances.
RIN3
, a RAS effector and RAB5-directed guanine nucleotide exchange factor (GEF), is highly expressed and enriched in human mast cells. SCF treatment of mast cells increased the amount of GTP-bound RAB5, and the degree of RAB5 activation correlated with the expression level of
RIN3
. At the same time, SCF caused the dissociation of a pre-formed complex of
RIN3
with BIN2, a membrane bending protein implicated in endocytosis. Silencing of
RIN3
increased the rate of SCF-induced KIT internalization, while persistent
RIN3
over-expression led to KIT down regulation. These observations strongly support a role for
RIN3
in coordinating the early steps of KIT endocytosis. Importantly,
RIN3
also functioned as an inhibitor of
mast cell
migration toward SCF. Finally, we demonstrate that elevated
RIN3
levels sensitize mastocytosis cells to treatment with a KIT tyrosine kinase inhibitor, suggesting the value of a two-pronged inhibitor approach for this difficult to treat malignancy. These findings directly connect KIT activation with a
mast cell
-specific RAS effector that regulates the cellular response to SCF and provide new insight for the development of more effective mastocytosis treatments.
...
PMID:RIN3 is a negative regulator of mast cell responses to SCF. 2318 84